Initial public offers (OPI) in the biopharmaceutical sector increased 68.4 percent to reach $ 8.52 billion worldwide in 2024, according to a new report.
The sector saw an increase in 2024, with 50 OPI completed raising $ 8.52 billion, of $ 5.06 billion raised in 2023 and marking the highest total value of IPO collected since 2021.
This rebound, driven by the trimming of interest rates of the United States Federal Reserve, marks the highest total since 2021, said Globaldata, a leading data and analysis company.
While it is cautious, investors show greater interest in companies with solid clinical data, pointing out a recovery in public markets and a change towards more advanced biopharmaceuticals.
The completed opis that raised more than $ 100 million almost doubled, of $ 4.39 billion in 15 opi in 2023 to $ 7.88 billion in 24 opi in 2024.
The increase in the high -value OPI number in 2024 suggests that, although public investors remain selective, the increase in capital availability due to interest rate cuts has facilitated investments in biopharmaceutical companies with a Valame Stronge, said Walue, said Walue Valame, Labyaa Life, Saidluis Globaldata said.
The largest biopharmaceutical OPI completed in 2024, the Dermatology Company based in Switzerland, Galderma, which raised $ 2.48 billion, according to the report.
The Galderma OPI followed an OPI planned in February 2022 that did not close, as well as Galderma postponing it to the OPI in March 2023 amid the market volatility.
Despite the general increase in the high IPO value, the discovery and the preclinical stage combense saw a fall of four times in the total value of the OPI of $ 490.6 million in 2023 to $ 112.5 million in 2024, which indicates a change in public investment, the investment preference, the investment preference.
However, OPI’s activity could be seen by an anticipated increase in private biopharmaceutical mergers and acquisitions in 2025, since companies seek to fill their pipes before the next expiration of patents, the report said.